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Abstract
Myristoylation is a lipid modification involving the addition of a 14-carbon unsaturated fatty acid, myristic acid, to the N-
terminal glycine of a subset of proteins, a modification that promotes their binding to cell membranes for varied biological
functions. The process is catalyzed by myristoyl-CoA:protein N-myristoyltransferase (NMT), an enzyme which has been
validated as a drug target in human cancers, and for infectious diseases caused by fungi, viruses and protozoan parasites.
We purified Caenorhabditis elegans and Brugia malayi NMTs as active recombinant proteins and carried out kinetic analyses
with their essential fatty acid donor, myristoyl-CoA and peptide substrates. Biochemical and structural analyses both
revealed that the nematode enzymes are canonical NMTs, sharing a high degree of conservation with protozoan NMT
enzymes. Inhibitory compounds that target NMT in protozoan species inhibited the nematode NMTs with IC50 values of 2.5–
10 nM, and were active against B. malayi microfilariae and adult worms at 12.5 mM and 50 mM respectively, and C. elegans
(25 mM) in culture. RNA interference and gene deletion in C. elegans further showed that NMT is essential for nematode
viability. The effects observed are likely due to disruption of the function of several downstream target proteins. Potential
substrates of NMT in B. malayi are predicted using bioinformatic analysis. Our genetic and chemical studies highlight the
importance of myristoylation in the synthesis of functional proteins in nematodes and have shown for the first time that
NMT is required for viability in parasitic nematodes. These results suggest that targeting NMT could be a valid approach for
the development of chemotherapeutic agents against nematode diseases including filariasis.
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Introduction
Nematode parasites are the causative agents of a large and
diverse group of infectious diseases that affect millions of people,
particularly in tropical and sub-tropical regions of the world.
Lymphatic filariasis and onchocerciasis are chronic, disabling,
neglected tropical diseases (NTDs) caused by filarial nematodes.
Currently more than 1.4 billion people in 73 countries are
threatened by lymphatic filariasis, with over 40 million incapac-
itated by the disease [1] Onchocerciasis occurs mainly in Africa
with more than 99% of the 26 million infected people living in 31
countries in sub-Saharan Africa [2]. Mass drug administration
(MDA) campaigns, involving annual large-scale treatment with
albendazole together with either ivermectin (where onchocerciasis
is endemic) or diethylcarbamazine citrate (where onchocerciasis is
not present) to cover the entire at-risk population irrespective of
disease status, form the foundation of attempts to control filarial
infections. The drugs interrupt transmission by killing juvenile
parasites but do not kill mature worms, and therefore multiple
rounds of treatment are required before adult worms eventually
die. In the absence of an adulticide, it is recommended that the
MDA should be continued for 4–6 years for lymphatic filariasis [1]
and 10–15 years for onchocerciasis [2]. Of particular concern to
the MDA programs in Africa is co-endemic loiasis which can result
in severe adverse neurological events following medication. The
limitations of existing treatments and concerns for emergence of
drug resistance [3] highlight the need for additional effective, safe
and affordable drugs to treat the populations affected by filarial
diseases.
One approach to anti-infective drug discovery involves target
repurposing, where targets are selected based on their homology to
a target for which a drug has already been identified for another
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species or indication. Existing knowledge of the biochemistry,
structure and medicinal chemistry around the target is leveraged
to enable rapid identification of new drug candidates. For
example, the rapid development of HIV protease inhibitors was
largely based on chemical expertise resulting from studies on
human aspartic proteases [4,5]. Target repurposing is a particu-
larly attractive strategy for NTD drug discovery as it can provide
an accelerated and more economical path to new treatments [6].
A key element to this approach is the identification of shared
protein sequences among organisms, which has been greatly
facilitated by the increased availability of genome sequences.
Functional genomic studies in the pathogen or a model organism
can validate candidate targets and guide a repurposing program.
The genome of the free-living nematode Caenorhabditis elegans
has been used extensively as a model to understand molecular
pathways common to nematodes and mammals on the basis of
conserved evolution. For more than 30 years C. elegans has been
employed in screening for anti-nematode compounds [7]. It has
also been used in pharmacology studies [8] and to gain insight into
the mechanism of action of known compounds, and the
development of drug resistance [9]. The ability to perform
forward and reverse genetic studies in C. elegans enables
comprehensive validation of putative drug targets, which is key
to the success of a target-based drug discovery approach. The
abundance of functional genomic data from C. elegans and the
high degree of genome sequence conservation between C. elegans
and the human filarial parasite Brugia malayi, a causative agent of
lymphatic filariasis, has enabled the prediction of potentially
essential genes in B. malayi that may be exploited as drug targets
[10].
The enzyme myristoyl-CoA:protein N-myristoyltransferase
(NMT, EC 2.3.1.97) has been extensively investigated as a drug
target in human cancer [11–13], and in infectious diseases caused
by viruses [13–15], pathogenic fungi [16], and parasitic protozoa
including Trypanosoma brucei [17–19], Trypanosoma cruzi [20],
Leishmania major [18], Leishmania donovani [21], and Plasmo-
dium falciparum [17,18,22]. NMT is an essential monomeric
enzyme responsible for the co- and post-translational modification
of proteins by transferring the fatty acid myristate (C14.0) from
myristoyl-CoA to N-terminal glycine resides of a peptide/protein
substrate, enabling their targeting to various membranes [23,24]
and/or activation and stabilization of the substrate protein [17].
Numerous biological studies have validated T. brucei NMT
(TbNMT) as a druggable target using the prototypic TbNMT
inhibitor DDD85646 [19,23].
In this study we performed detailed molecular and biochemical
studies on the NMT enzymes from C. elegans and the human
filarial parasite B. malayi. We validated NMT as a new nematode
drug target by performing genetic studies in C. elegans, and
generated initial validation data using chemical inhibition studies
with DDD85646 (and a related derivative DDD100870) in C.
elegans and B. malayi. We also predicted the downstream target
proteins in B. malayi that may be disrupted as a result of NMT
inhibition. These studies represent the first analysis of N-
myristoyltransferases from a helminth parasite, and demonstrate
the importance of lipidation in nematodes including filarial worms.
Our data strongly support repurposing N-myristoyltransferase for
development of new therapies against nematode infection includ-
ing filarial diseases.
Materials and Methods
Sequence and structural analysis of NMT proteins
Full-length NMT sequences from Brugia malayi
(XP_001896037), Caenorhabditis elegans (NP_498326.1), Loa loa
(XP_003141266.1), Trypanosoma brucei (EAN78792.1), Plasmo-
dium falciparum (AAF18461.1), Leishmania major (AAG38102.1),
Saccharomyces cerevisiae (NP_013296.1), Homo sapiens
(AAH06376.1) and Ascaris suum (ERG81997.1) were retrieved
from NCBI. B. malayi NMT was used to query additional
databases to identify unannotated orthologs in other sequenced
nematode genomes. The orthology assignments determined by
TBLASTN analysis were recovered and contig sequences were
assembled manually to produce a full-length protein sequence.
The following list of nematode NMT proteins were manually
curated in this manner:
Wuchereria bancrofti (http://www.broadinstitute.org/annotation/
genome/filarial_worms/Blast.html?sp=Stblastn; contigs WUBG_
03313.1, WUBG_18444.1, and WUBG_06452.1), Trichinella spir-
alis (https://www.wormbase.org/tools/blast_blat; GL622787,
Length=12041450), Dirofilaria immitis (http://xyala.cap.ed.ac.uk/
downloads/959nematodegenomes/blast/filareu.php; nDi.2.2.scaf
00055, Length=228449), Acanthocheilonema viteae (http://xyala.
cap.ed.ac.uk/downloads/959nematodegenomes/blast/filareu.
php; nAv.1.0.scaf00057, length = 84838), Litomosoides sigmodon-
tis (http://xyala.cap.ed.ac.uk/downloads/959nematodegenomes/
blast/filareu.php; nLs.2.1.scaf00231, length= 65134 and nLs.2.1.
scaf00078, length = 103883), Onchocerca volvulus (http://xyala.
cap.ed.ac.uk/downloads/959nematodegenomes/blast/filareu.php;
nOv_contig22006, length = 20337), and Onchocerca ochengi
(http://xyala.cap.ed.ac.uk/downloads/959nematodegenomes/
blast/filareu.php; nOo.2.0.Scaf00398, length = 32289).
Protein alignment was performed using the ClustalW alignment
software (http://www.genome.jp/tools/clustalw/) and displayed
using BOXSHADE (http://www.ch.embnet.org/software/BOX_
form.html). The residues involved in binding of L. major NMT to
myristoyl-CoA and DDD85646 determined from co-crystal
structural analyses were obtained from: http://www.rcsb.org/
pdb/explore/explore.do?structureId = 2wsa. A rooted phylogenet-
ic tree with branch length was generated using the UPGMA
(Unweighted Pair Group Method with Arithmetic Mean)
ClustalW software. Sequence identity values between B. malayi
and an ortholog were generated using BLASTP.
Author Summary
Lymphatic filariasis and onchocerciasis are neglected
tropical diseases caused by filarial nematodes. The
limitations of existing drugs to treat these infections
highlight the need for new drugs. In the present study, we
investigated myristoylation, a lipid modification of a subset
of proteins that promotes their binding to cell membranes
for varied biological functions. The process is catalyzed by
N-myristoyltransferase (NMT), an enzyme which has been
validated as a drug target in protozoan parasites. We
performed kinetic analyses on Caenorhabditis elegans and
Brugia malayi NMTs. NMT inhibitors were active against B.
malayi microfilariae and adult worms, and C. elegans in
culture. RNA interference and gene deletion in C. elegans
further demonstrated that NMT is essential for nematode
viability. Our genetic and chemical studies indicate the
importance of myristoylation in the synthesis of functional
proteins in nematodes and have shown for the first time
that NMT is required for viability in parasitic nematodes.
These results suggest that targeting NMT could be a valid
approach for the development of new therapies against
nematode infection including filarial diseases.
Nematode N-myristoyltransferase
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A homology model of the B. malayi NMT structure was built
based on several structurally characterized NMT’s, including
enzymes from Leishmania donovani (2wuu), Plasmodium vivax
(4a95), and Saccharomyces cerevisiae (2p6f) using the PHYRE
program (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.
cgi?id = index). The FASTA sequence for B. malayi was uploaded
to the Protein Homology/analogY Recognition Engine V 2.0
(Phyre2) server, where models were automatically generated using
the best possible template model [25]. The predicted structure of
B. malayi NMT was then compared to the structure of L. major
NMT (2wsa) bound to myristoyl-CoA and inhibitor DDD85646
using the UCSF Chimera software [26].
Expression and purification of nematode NMT enzymes
Full-length CeNMT cDNA was reverse transcribed from total
C. elegans RNA and then amplified using the following primers:
(GATCGGGAATTCATATGTCCCACGGACACAGTC) and
(GATCCCGCTCGAGTTGAAGAACAAGCCCGATTT) con-
taining a NdeI or XhoI restriction site (underlined), respectively,
to enable cloning into the corresponding sites of the expression
vector. BmNMT (Bm1_22900) was a synthetic (codon-optimized)
version of the gene (GenScript Corporation, Piscataway, NJ)
designed to optimize expression in E. coli. Each nematode NMT
gene was cloned into the pET19b vector to express a fusion
protein with a 10-His tag at the N-terminus. The insert was then
fully sequenced for verification. Plasmids were transformed into
the E. coli strain NiCo21(DE3) (NEB) for protein expression.
Cultures were grown at 37uC and induced with 0.4 mM IPTG at
16uC overnight. The His-tagged proteins were extracted in lysis
buffer (20 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole,
pH 8.0) containing protease inhibitors (Complete EDTA-free
Protease Inhibitor, Roche), and purified on 1 mL HisTrap HP
(GE Healthcare) using an A¨KTA-FPLC system (GE Healthcare).
Protein was eluted using a linear (0–100%) gradient of elution
buffer (20 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole,
pH 8.0). Fractions containing NMT were pooled and dialyzed into
storage buffer (20 mM Tris-HCl, 100 mM NaCl, 2 mM DTT,
2 mM EGTA, 2 mM EDTA, and 50% glycerol, pH 7.5).
Biochemical assays
Nematode NMT proteins were assayed using synthetic peptides
GGVMSYRRR (ARL-1 ADP ribosylation factor related protein),
GHSHSTGKRR (ABL-1 tyrosine kinase) and GCLFSKERR
(SRC-1 tyrosine kinase), derived from N-terminal sequence of
several C. elegans N-myristoylated proteins. One or two basic
amino acids (underlined) were added at the C-terminal end of the
peptide to generate a positive charge at pH 7.3. The NMT assay
was performed as described with some minor modification
[18,27]. Reactions were carried out in a final volume of 50 mL
containing 30 mM Tris-HCl buffer (pH 7.5), 0.5 mM EDTA,
0.45 mM EGTA, 4.5 mM 2-mercaptoethanol, 1% Triton X-100,
1 mM peptide and 5 ng purified enzyme. N-myristoylation was
initiated by the addition of 0.5 mM myristoyl-CoA. Myristoyl-
CoA was prepared by mixing equal volumes of cold
myristoyl-CoA (1 mM, Chem-Impex International) with [3H]
myristoyl-CoA (5 mM, 42 Ci/mmol, Perkin Elmer). After a
10 minute incubation at 30uC, the reaction was terminated by
spotting 25 mL reaction mixture onto P81 phosphocellulose paper
(Whatman). The paper was dried under a heat lamp and washed
three times for 10 minutes in 20 mM Tris-HCl pH 7.5 prior to
scintillation counting using a Liquid scintillation Analyzer (Tri-
Carb 2900 TR, Perkin Elmer). All reactions were performed in
duplicate, and reactions performed in the absence of enzyme, or
peptide, were included as controls. Background radioactivity
values generated from control samples were subtracted from the
values obtained from experimental samples.
To determine the kinetic constants: Km, Vmax, Kcat and Kcat/
Km of B. malayi and C. elegans NMT for myristoyl-CoA, the
concentration of myristoyl Co-A was varied from 0.1–50 mM in
the presence of 1 mM peptide (ABL-1) and 5 ng enzyme.
Reactions were performed in triplicate. Optimum fitting of data
to the Michaelis-Menten equation was calculated using non-linear
regression software (http://www.colby.edu/chemistry/PChem/
scripts/lsfitpl.html). One unit of NMT activity is defined as
1 pmol of myristoylated peptide formed per min.
Inhibition assays for compounds DDD85646 and DDD100870
were performed in a final volume of 50 mL containing 10 mM Tris
pH 7.5, 0.5 mM DTT, 0.1 mM EDTA, 10 nM enzyme and
5 mM myristoyl-CoA (as above). Enzyme mixtures were preincu-
bated with various concentrations of each compound (0.0025–
1 mM) dissolved in DMSO for 7.5 min at 25uC then the reactions
were initiated by adding peptide substrate (ABL-1, 12.5 mM).
Following a 15 minute incubation at 25uC, reactions were
terminated by spotting 25 mL onto P81 phosphocellulose paper,
washed, dried and prepared for scintillation counting as described
previously. Reactions performed in the absence of inhibitor or
peptide were included as controls. Experiments were performed in
triplicate. Mean IC50 values were determined in the concentration
range of 2.5–10 nM.
C. elegans methods
C. elegans culture and handling were performed following
standard procedures [28]. N2 strain var. Bristol was used as wild-
type [29]. Mutant strains (NL4256 rrf-3(pk1426), lin-
15b(n744);eri-1(mg366)) were obtained from the C. elegans stock
center (CGC, University of Minnesota) and also (nmt-1(tm796)/
hT2[qla48]) from Dr. S. Mitani (National Biosource Project of
Japan, Tokyo Women’s Medical University School of Medicine,
Tokyo).
Establishing the essential function of NMT in C. elegans
Three C. elegans strains were used for RNAi knockdown of
NMT: C. elegans wild-type and two RNAi sensitive C. elegans
strains, one containing a mutation in rrf-3 [30], and a second
strain carrying mutations in both eri-1 and lin-15B I [31]. RNAi
was performed by feeding an Escherichia coli strain expressing
dsRNA [32]. Full-length NMT cDNA was subcloned into the
feeding vector pL4440. HT115 E. coli transformed with this
construct were spread on agar plates containing NGM supple-
mented with 1 mM isopropylthio-b-D-galactoside (IPTG, Sigma)
and 50 mg/mL ampicillin, and incubated overnight at room
temperature to induce dsRNA expression. RNAi assays were
carried out by feeding L4-staged worms HT115 E. coli expressing
dsRNA corresponding to NMT or pL4440 plasmid vector without
CeNMT. The relative health of the progeny of each worm was
determined qualitatively by its appearance relative to the controls
over the course of several days. For each RNAi experiment, 50
worms were assayed from each of the 3 strains.
Phenotypic analyses were also performed using the mutant
strain nmt-1(tm796)/hT2[qls48]. To verify the deletion, genomic
DNA was prepared from a single mutant animal, and one worm
from heterozygous and wild-type strains using standard methods
[33]. The deletion was confirmed on the basis of the change in size
of a PCR product using forward primer TCAACTGATTG-
CACCGTCAT and reverse primer AAGCGGAACATGGAAT-
CATC. PCR reactions were carried out using 25 picomoles of
each primer and LongAmp DNA Polymerase (NEB). Bands of the
expected sizes were obtained.
Nematode N-myristoyltransferase
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Testing compounds for activity against C. elegans and B.
malayi
Wild-type C. elegans were grown on NGM plates seeded with
OP50 E. coli. Compound screening commenced with L4-staged
worms placed into a well of a sterile 96-well micro titer plate
(Falcon 3072) containing a 100 mL suspension of previously frozen
HB101 E. coli bacteria in S medium. Various concentrations of
compound (25, 50 or 100 mM) or DMSO (control) were then
added. Plates were maintained at 20uC in a humidity chamber for
7 days. Worm growth and development was scored daily by
measuring a decrease in OD600 nm resulting from consumption of
E. coli, and by microscopic examination of the size and number of
F1 progeny produced on day 3 of the experiment. For each
condition, 10 L4-stage worms were used, and the average 6
standard deviation was plotted.
Living B. malayi worms including adult female, adult male and
microfilariae were purchased from TRS labs (Athens, GA). Worms
were washed extensively with RPMI 1640 medium prior to culture
in RPMI 1640 medium supplemented with 2 mM glutamine, 10%
Fetal Calf Serum (Gibco) and 100 mg/mL streptomycin, 100
units/mL penicillin, 0.25 mg/mL amphotericin B (Sigma) at 37uC,
in 5% CO2. After overnight recovery, adult worms were separated
into 3 different groups each containing either 8 females (2 worms/
well) or 12 males (3 worms/well). Compounds (DDD85646 or
DDD100870) at 100 mM or 50 mM, or 1% DMSO were added to
the culture medium. Microfilariae were cultured in 24-well plates
and compounds were added to the culture medium at a final
concentration of 100 mM, 50 mM, 25 mM or 12.5 mM. Experi-
ments were performed in at least triplicate. The culture media
were replaced every other day with fresh media containing
compound or DMSO only. Parasite motility was video-recorded
daily and analyzed at the end of the experiment (day 7). Parasite
motility was assessed and scored in the range 0–20 (most motile).
Observations are expressed as a percentage of the motility relative
to the motility scored on day 0 of the experiment. Counting
numbers of parasites on days 1, 3 and 5 assessed production of
microfilariae from female worms. The data obtained from
triplicate samples are expressed as mean 6 standard deviation.
Bioinformatic prediction of B. malayi NMT substrates
To identify potential targets for N-terminal glycine myristoyla-
tion in B. malayi, predicted myristoylated proteins in the proteome
of C. elegans were retrieved (http://mendel.imp.ac.at/myristate/
myrbase/28731NEgenpept227MYRclusterV05.html) and used to
query the genome of B. malayi. Homologs with a BLASTP E-
Value ,e210 were analyzed using the MYR predictor (http://
mendel.imp.ac.at/myristate/SUPLpredictor.htm) to predict myr-
istoylation sites. Protein sequences that were scored as ‘‘Reliable’’
or ‘‘Twilight zone’’ were retained and duplicates were discarded.
Results
Distribution and conservation of N-myristoyltransferases
in nematodes
Both C. elegans and B. malayi genomes contain a single copy
NMT gene predicted to encode a N-myristoyltransferase which
catalyzes the covalent attachment of fatty acid myristate to the N-
terminal glycine of proteins (Fig. 1). In C. elegans, gene T17E9.2
encodes three isoforms: A (450 aa, 51 kDa, pI 7.6), B (452 aa,
51 kDa, pI 7.9) and C (403 aa, 46 kDa, pI 8.6). All isoforms share
the same amino acid sequence, with isoforms A and B possessing
an additional 47 or 49 amino acids at the N-terminus, respectively.
BmNMT encodes one 472 aa protein (XP_001896037) of 54 kDa
with a pI of 6.6. C. elegans and B. malayi NMTs share
approximately 60% amino acid identity and 75% similarity to
each other (Fig. 2).
To investigate if NMT is present in other nematodes, BmNMT
was used as a query to search ,300,000 EST sequences at
Nematode.net [34] that are available for 30 different parasitic
nematodes species. Matching NMT sequences were found in free-
living nematodes and a highly diverse group of parasitic nematode
species found in humans (Strongyloides stercoralis), animals
(Strongyloides ratti, Ancylostoma caninum, Teladorsagia circum-
cincta) and plants (Meloidogyne hapla, Heterodera glycines)
representing four major clades of the phylum Nematoda (data
not shown). To determine the degree of conservation of the
enzyme among nematodes, full-length sequences (Fig. S1) were
obtained for a number of species (B. malayi, C. elegans, Loa loa,
Ascaris suum, Wuchereria bancrofti, Trichinella spiralis, Dirofi-
laria immitis, Acanthocheilonema viteae, Litomosoides sigmodontis,
Onchocerca volvulus and Onchocerca ochengi). The relationship of
the nematode enzymes to other eukaryotic (Homo sapiens,
Saccharomyces cerevisiae) and prokaryotic (Trypanosoma brucei,
Plasmodium falciparum, Leishmania major) NMTs was also
examined. Phylogenetic tree analyses (Fig. 2) indicated that the
filarial nematode sequences (Clade III) form a close cluster with a
high degree of conservation (greater than 88% identity, 94%
similarity). Trichinella spiralis (Clade I) and Ascaris suum (Clade
III) enzymes are 73% and 84% similar to B. malayi NMT,
respectively. B. malayi NMT also shares significant similarity to
protozoan (56–62%), human (64%) and yeast (59%) enzymes.
Multiple sequence alignment of B. malayi NMT and orthologs
from Loa loa, O. volvulus, C. elegans, S. cerevisiae, L. major, T.
brucei and H. sapiens also revealed conservation in the residues
involved in binding to myristoyl-CoA (Fig. S2) [23]. Consistent
with other NMT enzymes, the nematode NMTs are divergent at
their N-termini, a region not involved in substrate binding [21,23],
and all possess an N-terminal extension not present in the
previously studied NMTs from protozoa or yeast.
A homology model indicates that B. malayi NMT possesses a
canonical NMT structure with a typical NMT fold characteristic
of the Acyl-CoA N-acyltransferases superfamily [35]. The NMT
fold basically consists of a large saddle-shaped b-sheet that is
flanked on both of its faces by several helices (Fig. 3A). The model
generated is based on the structurally characterized NMTs from
Saccharomyces cerevisiae (c2p6fA) and Leishmania donovani
(2wuu), and is predicted to have a 100% confidence level.
When the predicted B. malayi NMT structure is compared with
the structure of the Leishmania major NMT (2wsa) enzyme bound
to myristoyl-CoA and inhibitor DDD85646, a high degree of
conservation was revealed in the myristoyl-CoA binding site as
well the drug binding pocket (Fig. 3B). The 2 small helixes
(Fig. 3B, arrow) formed by an insertion of 21 amino acids in L.
major NMT are replaced with a loop in B. malayi NMT that is
unlikely to have any major effects on the binding of substrate or
inhibitor.
Recombinant nematode NMT proteins are active N-
myristoyltransferases
To verify their NMT activities, recombinant C. elegans NMT
(51 kDA) and B. malayi NMT (54 kDA) were expressed, purified
and assayed using several synthetic peptides containing a
canonical myristoylation motif derived from the N-terminal
sequence of three C. elegans proteins. BmNMT (Bm1_22900)
was a synthetic (codon-optimized) version (Fig. S3) of the gene
(GenScript Corporation, Piscataway, NJ) designed to optimize
expression in E. coli. Expression studies using BmNMT cDNA
isolated by RT-PCR (Fig. S3) generated largely insoluble protein.
Nematode N-myristoyltransferase
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Figure 1. Reaction catalyzed by Myristoyl CoA:protein N-myristoyltransferase (NMT). NMT catalyzes the covalent attachment of fatty acid
myristate to the N-terminal glycine of a subset of proteins. The fatty acid moiety is provided by myristoyl-CoA, which binds to the apo-enzyme first,
forming a binary complex. This complex then binds the substrate protein and the reaction occurs. Subsequently, CoA is released, followed by release
of the myristoylated protein product [17].
doi:10.1371/journal.pntd.0003145.g001
Figure 2. Evidence for the presence of N-myristoyltransferase (NMT) in nematodes and conservation of NMT among prokaryotes
and eukaryotes. Rooted phylogenetic tree analysis of NMT and various homologs. Deduced open reading frames of NMTs were used to generate
the phylogram. Branch length was generated using ClustalW (http://www.genome.jp/tools/clustalw/). The percentage of amino acid identity and
similarity between B. malayi NMT and orthologs are shown.
doi:10.1371/journal.pntd.0003145.g002
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Both recombinant proteins displayed similar levels of activity using
the various peptides, with the highest activity observed with ABL-1
(Fig. 4).
Kinetic analyses of recombinant nematode NMTs were
performed using ABL-1 as the peptide. The Km, Vmax, Kcat and
Kcat/Km for myristoyl-CoA were determined for both enzymes
(Fig. S4). The C. elegans Km=12.260.91 mM) and B. malayi
(Km= 4.460.12 mM) enzymes showed similar affinities for myr-
istoyl-CoA. Kcat/Km values were also comparable for both C.
elegans (0.13 s21 mM21) and B. malayi (0.15 s21 mM21) NMTs.
While these values cannot be compared directly with those
measured for the NMTs of other species as the assay substrates
and conditions are different, the data obtained are of the expected
order of magnitude.
Inhibition of nematode NMT activity using anti-
trypanosome compounds
DDD85646 is a known inhibitor of NMT enzymes from several
trypanosomatids. DDD85646 inhibits the proliferation of T. brucei
in culture with.200 fold selectivity over mammalian cells [19,23].
Given the degree of conservation observed in comparative
sequence and structural analyses between nematode and trypano-
some NMT enzymes, we examined the potency of DDD85646
and its analogue DDD100870 (Fig. 5) against C. elegans and B.
Figure 3. Modeling the structure of B. malayi NMT and structural comparison with Leishmania major NMT. (A) Ribbon diagram of the
predicted crystal structure of NMT from B. malayi. (B) Comparison of B. malayi NMT (tan) with L. major NMT (blue: 2wsa). An overlay of the structure of
these enzymes using UCSF Chimera [26] reveals a nearly identical conformation of the binding sites for myristoyl-CoA (yellow) and inhibitor
DDD85646 (magenta). The 2 small helixes (arrow) formed by an insertion of 21 amino acids in L. major NMT are replaced with a loop in B. malayi NMT.
doi:10.1371/journal.pntd.0003145.g003
Figure 4. Biochemical analysis of recombinant C. elegans NMT and B. malayi NMT. Purified recombinant B. malayi NMT and C. elegans NMT
enzymes myristoylate several synthetic peptide substrates (ARL-1 ADP ribosylation factor related protein; ABL-1 tyrosine kinase and SRC-1 tyrosine
kinase). No activity was detected in the absence of peptide. Enzyme activity is expressed as radioactivity in disintegrations per minute (DPM).
doi:10.1371/journal.pntd.0003145.g004
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malayi NMT proteins (Fig. 6). A dose-dependent inhibition of C.
elegans NMT activity with an IC50 value of,10 nM was observed
for both compounds (Fig. 6A). The IC50 value of DDD85646 for
B. malayi NMT is also ,10 nM. DDD100870 was a more potent
inhibitor of the filarial enzyme since an IC50 value of 2.5 nM was
obtained.
C. elegans NMT plays an essential role in development
To investigate the importance of C. elegans NMT in vivo,
phenotypic analyses were performed on a strain carrying a
deletion allele (nmt-1(tm796)/hT2[qls48]) (Fig. 7A, B) and on
worms with reduced endogenous activity resulting from RNAi
[36]. The deletion was confirmed by PCR analysis. DNA prepared
Figure 5. Structures of the NMT inhibitors, DDD85646 and
DDD100870.
doi:10.1371/journal.pntd.0003145.g005
Figure 6. Inhibition of C. elegans (A) and B. malayi (B) NMTs using DDD85646 and DDD100870. Enzyme mixtures were preincubated with
various concentrations of each compound (0.0025–1 mM). Reactions performed in the absence of inhibitor (positive control) or peptide (negative
control), were included. Background radioactivity values generated from ‘non-peptide’ control samples were subtracted from the values obtained
from experimental samples. Percent activity relative to the positive control 6 propagation of error (http://laffers.net/blog/2010/11/15/error-
propagation-calculator/) was determined. Assays were performed in triplicate.
doi:10.1371/journal.pntd.0003145.g006
Figure 7. NMT is essential in C. elegans. (A) Phenotypic analyses
were performed using the mutant strain nmt-1(tm796)/hT2[qla48].
Predicted genomic organization of CeNMT and location of the deletion
are shown. Boxes and lines denote exons and introns respectively. To
verify the deletion genomic DNA was prepared from a single mutant
animal ‘‘2/2’’, and one worm from heterozygous ‘‘+/2’’ and wild-type
‘‘+/+’’ strains using standard methods. (B) Primers were designed to
flank the deletion site and the deletion was confirmed on the basis of
the change in size of a PCR product. Bands of the expected sizes were
obtained. (C) RNAi knockdown of NMT in C. elegans. Three C. elegans
strains were used for RNAi knockdown of NMT: C. elegans wild-type and
two RNAi sensitive C. elegans strains, one containing a mutation in rrf-3,
and a second strain carrying mutations in both eri-1 and lin-15B. RNAi
was performed by feeding worms E. coli expressing dsRNA correspond-
ing to NMT, or pL4440 plasmid vector without CeNMT.
doi:10.1371/journal.pntd.0003145.g007
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from wild-type and heterozygous worms generated a band of
approximately 1295 bp, whereas a smaller band (799 bp) was
obtained from both heterozygous and mutant animals (Fig. 7B).
The C. elegans nmt gene comprises four exons and the size of the
smaller band is consistent with a deletion involving exon 1 and
exon 2 (partial) (Fig. 7A). Three C. elegans strains were used for
RNAi knockdown of NMT: C. elegans wild-type and two RNAi
sensitive C. elegans strains, one containing a mutation in rrf-3
[30], and a second strain carrying mutations in both eri-1 and lin-
15B [31]. Homozygous nmt-1(tm796)/hT2[qla48] animals had an
obvious phenotype marked by a maternal effect larval lethality
with no viable worms present in the F2 population. In wild-type C.
elegans, RNAi knockdown of CeNMT expression resulted in a
severe growth defect, while in the RNAi sensitive strains (rrf-3 and
eri-1; lin-15B) larval arrest was observed (Fig. 7C). No abnormal
phenotype was observed for these three strains when fed E. coli
containing the pL4440 plasmid without CeNMT. These data
demonstrate depletion of NMT activity in nematodes causes
severe developmental defects and establishes the requirement of
NMT for viability in C. elegans.
Inhibition of nematode growth using NMT inhibitors
The potent activities of DDD85646 and DDD100870 in
nematode NMT activity assays and requirement of NMT for
viability in C. elegans prompted evaluation of the compounds for
in vivo activity against C. elegans and B. malayi. C. elegans L4s
were treated with 25, 50 or 100 mM of each compound and worm
growth and development was scored daily by measuring a
decrease in OD600 nm resulting from consumption of E. coli
(Fig. 8A) and by microscopic examination of the size and number
of F1 progeny (Fig. 8B). In control worms exposed to DMSO
alone there was a rapid consumption of the E. coli food source as
indicated by a decline in OD600 value. DDD100870 treated
worms showed slower feeding/growth that was dose dependent,
with 100 mM compound resulting in almost complete inhibition of
feeding. In contrast, 100 mM of the related compound DDD85646
only slightly delayed the clearance of bacteria from the culture. On
day 3, DDD100870 treated worms showed a concentration
dependent decline in the number of F1 progeny produced
(Fig. 8B) while no such effect was observed for DDD85646 (data
not shown). The progeny of controls averaged (140 worms)
930 mm in length, whereas worms treated with 100 mM
DDD100870 resulted in no progeny or fewer progeny of smaller
size (360 mm long). Worms exposed to 50 and 25 mM
DDD100870 showed a dose-dependent decline in the number of
F1 progeny produced and their size.
Adult worms and microfilariae of B. malayi were cultured in the
presence of both NMT inhibitors (Fig. 9). The parasites were
observed for changes in motility and production of microfilariae by
adult female worms compared to control worms exposed to 1%
DMSO. Both DDD85646 and DDD100870 exerted a significant
and profound effect on B. malayi, though DDD100870 (effective
against C. elegans) was more potent than DDD85646 (Fig. 9). A
decline in the motility of exposed adult female (Fig. 9A) and male
(Fig. 9B) worms was apparent within 24 hours of treatment. By
day 6, DDD100870-treated adult worms showed little movement,
while the control worms still displayed vigorous activity. Interest-
ingly, DDD85646 displayed more potent activity against female
worms than male worms. Microfilariae were more sensitive than
adult worms to both compounds with concentrations as low as
12.5 mM immobilizing the worms within 24 hours of exposure
(Fig. 9C). Microfilariae production by female worms was also
severely affected by treatment and a decline was apparent at
24 hours post culture (Fig. 9D).
Potential N-myristoylation substrates in B. malayi
To predict downstream target proteins that may be disrupted
due to NMT inhibition by compounds DDD85646 and
DDD100870, a bioinformatics approach was used to identify
potential targets for N- myristoylation in B. malayi. Predicted
myristoylated proteins in the proteome of C. elegans (145 clusters)
were retrieved from MYRbase and used to query the B. malayi
genome. A total of 40 unique protein sequences were obtained; 30
scored ‘‘reliable’’ and 10 designated ‘‘twilight zone’’ (Table 1).
The putative substrates are involved in diverse and essential
pathways. These include ADP-ribosylation factors, hydrolases,
protease activity, receptor activity and several are protein kinase
domain containing proteins. In C. elegans, the majority of the
predicted substrates (31/40) display multiple developmental
defects and impaired survival in RNA interference assays
(Table 1), and include the phenotypes we observed in RNAi
knockdown of CeNMT and in mutant worms carrying a deletion
allele. We cannot exclude the possibility that NMT has unknown
functions in addition to myristoyltransferase activity. However, it is
most likely that the pleiotropic effects observed are likely caused by
inhibition of myristoylation of multiple important substrates,
demonstrating the requirement of protein myristoylation in
nematodes.
Discussion
NMT inhibitors are being investigated by various groups for
diseases including leishmaniasis [18], Chagas’ disease [20–21],
African sleeping sickness [17–19,23], and malaria [17,18,22,37].
The protozoan and nematode enzymes share significant similarity
to human NMT yet some compounds show selectivity largely as a
result of affinity and differences in the off-rates. Current drug
development projects are focusing on this parameter for optimi-
zation of selectivity [23]. At the time of writing all of these
programs are in the discovery phase seeking to identify clinical
candidates.
To our knowledge, there have been no biochemical studies on
NMT enzymes, or their substrates, from any helminth parasite.
Even in the widely studied free-living nematode C. elegans, there is
a paucity of information available. Fatty acylation of polypeptides
has been experimentally demonstrated in extracts including
myristoylation following metabolic labeling of C. elegans using
[3H]-myristic acid [38,39]. However, only one of many labeled
proteins in the extracts was identified, namely the catalytic subunit
of cAMP-dependent protein kinase [38].
In this study we established the importance of myristoylation in
C. elegans and also in a parasitic nematode responsible for
lymphatic filariasis. Our finding of highly conserved NMT
sequences in the genomes of many nematode species suggests
that myristoylation is likely required for the synthesis of functional
nematode proteins. Comparative sequence and structural analyses
between nematode and T. brucei NMT enzymes enabled us to
consider a drug repurposing strategy using the prototypic TbNMT
inhibitor, DDD85646, which has potent activity against T. brucei
enzyme and cells in culture (nM range) [19,23]. The compound is
also active against T. cruzi, although ,10–20 -fold more
compound is required for enzyme inhibition, and ,1000-fold
more (mM range) to inhibit parasite growth [40]. The cause for the
reduced potency against intact T. cruzi is not known but
differences in the rate of plasma membrane turnover, cellular
pharmacokinetics of drug uptake or efflux, or differences in other
essential biological functions requiring N-myristoylation have been
proposed [40]. DDD85646 and DDD100870 are potent inhibitors
of the nematode enzymes (nM range), and possess activity against
Nematode N-myristoyltransferase
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larval stages and adult worms of B. malayi (mM range).
Interestingly, despite comparable IC50 values for both compounds
in C. elegans NMT enzyme assays, only compound DDD100870
showed micromolar activity against intact C. elegans. The need for
substantially more compound to detect activity against the
nematode has also been reported in other enzyme-based screening
campaigns for new filarial leads [41–43]. It is thought that the
outermost layer of the cuticle is the main barrier to penetration of
drugs, stains, and other chemicals [44,45]. Further studies are
needed to determine the physicochemical factors that favor the
absorption of compounds in nematodes. This knowledge would
facilitate confirming the linkage between enzyme inhibition and
organism activity, and greatly expedite the discovery and
optimization of anthelmintic leads.
We also pursued a genetic approach to assess the requirement of
the enzyme in C. elegans. Knockdown of endogenous activity
Figure 8. Effect of NMT inhibitors on C. elegans growth.Wild-type C. elegans were grown on NGM plates seeded with OP50 E. coli. Compound
screening (DDD85646 and DDD100870) commenced with L4-staged worms placed into a well of a sterile 96-well micro titer plate (Falcon 3072)
containing a 100 mL suspension of previously frozen HB101 E. coli bacteria in S medium. Various concentrations (25, 50 or 100 mM) of compound or
DMSO (control) were then added. Plates were maintained at 20uC in a humidity chamber for 7 days. Worm growth and development was scored daily
by measuring a decrease in OD600 nm resulting from consumption of E. coli, (A) and by microscopic examination of the number of F1 progeny
produced and size of worms treated with DDD100870 (B). For each condition, 10 L4-stage worms were used, and the average 6 standard deviation
was plotted.
doi:10.1371/journal.pntd.0003145.g008
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using RNAi resulted in severe growth defects and larval arrest, and
gene deletion caused maternal effect lethality with no viable
worms present in the F2 population. The importance of the gene
in B. malayi can be inferred from our RNAi analysis since there is
good concordance between the phenotypes resulting from RNAi
knockdown of orthologous genes in parasitic nematodes and C.
elegans [46–48].
Essential roles for NMT have also been genetically validated in
other pathogens including pathogenic fungi Candida albicans [49]
and Cryptococcus neoformans [50], and the kinetoplastid protozo-
an parasites L. major [51,52], L. donovani [21], T. cruzi [40], and
T. brucei [52]. Overexpression of NMT in T. brucei causes gross
changes in parasite morphology, including the subcellular
accumulation of lipids, leading to cell death [51]. In Drosophila,
a null mutation of the single NMT gene causes disruption of the
actin cytoskeleton and ectopic apoptosis in embryos, possibly
attributed to loss of function of myristoylated tyrosine kinases [53].
Detailed studies performed in T. brucei indicate that inhibition
of myristoylation of multiple substrates accounts for the effective-
ness of NMT inhibitors in cell culture and in vivo [19]. While
there remains incomplete knowledge of the targets of NMT in T.
brucei and their subsequent downstream effects, trypanosomatids
mainly use myristate for incorporation into glycol-phosphatidyli-
nositol (GPI) anchors that tether the major surface glycoproteins
and glycoconjugates to the external surface of the plasma
membrane [54]. Recent bioinformatics analysis suggests there
Figure 9. Effect of NMT inhibitors on B. malayi in vitro. Living B. malayi worms including adult female (A), adult male (B) and microfilariae (C)
were exposed to NMT inhibitors for 7 days. Compounds DDD85646 (orange) or DDD100870 (blue) at 100 mM (circle) or 50 mM (square) or 1% DMSO
(grey) were added to adult worm culture. Microfilariae (mf) were cultured in the presence of compounds at a final concentration of 100 mM (circle),
50 mM (square), 25 mM (diamond) or 12.5 mM (triangle). Experiments were performed in triplicate. The culture media were replaced each day with
fresh media containing compound or DMSO (grey) at corresponding concentrations. Parasite motility was video-recorded daily and observations
expressed as a percentage of the motility relative to the motility scored on day 0 of the experiment. Production of microfilaria from female worms (D)
was assessed on days 1, 3 and 5. The data obtained from triplicate samples are expressed as mean 6 standard deviation.
doi:10.1371/journal.pntd.0003145.g009
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Table 1. Listing of predicted B. malayi NMT substrates.
B. malayi locus Myristoylation motif Score Protein information C. elegans homolog
Bm1_33335 GGNNSTPKSDTMMDHQP 3.982 hypothetical protein F46C8.3
Bm1_01010 GCTMSQEERAALERSRM 3.961 guanine nucleotide-binding
protein G-o protein alpha subunit
C26C6.2 *
Bm1_20595 GNYKSRPPSSCADELKK 3.617 Protein kinase domain containing
protein
C24A1.3a *
Bm1_07670 GGRQSSQVSHEVAQSEV 3.327 cytochrome C-type heme lyase T06D8.6 *
Bm1_36040 GNCFSGSPRQSSPSSDI 2.626 SRC-1, putative Y92H12A.1 *
Bm1_54125 GNSGSTNIPGGGTEGYH 2.584 golgi reassembly stacking
protein 2, putative
Y42H9AR.1
Bm1_51340 GSCQSQEAQEQLARNKA 2.509 Guanine nucleotide-binding
protein alpha-3 subunit, putative
C34D1.3 *
Bm1_52520 GQQQSGFGGKREDRGGG 2.411 Probable 26S protease regulatory
subunit 4
F29G9.5 *
Bm1_44925 GNALCCLQDSSSAARSK 2.368 cyclin fold protein 1 variant b ZK353.1b
Bm1_35125 GCVNSIDQNAKARSKQI 2.304 GTP-binding regulatory protein
alpha chain - starfish, putative
T07A9.7
Bm1_03585 GQIASIRRRASVPNVTN 2.205 hypothetical protein C11H1.3 *
Bm1_15680 GSSQSYEESNRSDDLPK 1.780 hypothetical protein M176.3 *
Bm1_01525 GQERSILSRKSQNTIEM 1.736 hypothetical protein F54B11.5
Bm1_53985 GASLTSPLPHRPPTSVC 1.705 hypothetical protein
Bm1_53985
T23F11.3b
Bm1_32000 GNGQSSNDTNIPSSHSF 1.704 hypothetical protein F59E12.11 *
Bm1_45820 GGRCSRRAPSPTHPKLS 1.688 Protein kinase domain containing
protein
ZK909.2h *
Bm1_26080 GQFLSTTASVDEESILR 1.646 Glutaredoxin family protein ZK121.1a *
Bm1_16785 GNTGSSLTDLNLFSKGG 1.635 calcium and integrin binding family
member 2
F30A10.1 *
Bm1_28345 GAYLSKPITEKISECGG 1.596 Protein phosphatase 2C containing
protein
T23F11.1
Bm1_34880 GAATSGLQSQMQQEHDP 1.384 LD28933p F20D1.1
Bm1_31655 GQQQSAFVVEIASSRFG 1.301 hypothetical protein Y67A10A.7
Bm1_07365 GKAGSKVKNYSKIKKNN 1.146 TLD family protein K08E7.1 *
Bm1_41730 GSCLGKKSSTTILEAVH 0.948 protein-tyrosine kinase F49B2.5 *
Bm1_38795 GLTISGLFGRLFGKKQV 0.755 ADP-ribosylation factor 4 F57H12.1 *
Bm1_55795 GTRLSVSLEDPEVSPRT 0.189 Probable NADH-ubiquinone
oxidoreductase B18 subunit
D2030.4 *
Bm1_04790 GISTSMQKDSTVLSCYG 0.183 Platelet-activating factor
acetylhydrolase
C52B9.7a *
Bm1_46940 GNAAGSIKRSKSIGTWI 0.105 hypothetical protein C52A11.2 *
Bm1_12460 GNLFGKQRPALTPVSQQ 0.076 FLJ11749-like Y65B4A.3 *
Bm1_28970 GTTIAIKRKGTGESGKS 20.192 G-protein alpha subunit, putative C26C6.2 *
Bm1_51315 GICQSQEEKTMVAKSRA 20.743 Guanine nucleotide-binding
protein alpha-3 subunit, putative
E02C12.5 *
Bm1_36120 GIKSSKPKLSKEDLDFL 20.798 Neuronal calcium sensor 2 F10G8.5 *
Bm1_17230 GNRESSTSLTSLTSLIS 20.812 Ubiquitin carboxyl-terminal
hydrolase family protein
ZK328.1b *
Bm1_54455 GKLLSKIFGKREMRILM 21.097 ADP-ribosylation factor 6 B0336.2 *
Bm1_39660 GNMEASGREMDNPDAEE 21.101 map kinase activated protein
kinase protein 2, isoform b
F42G8.3b *
Bm1_43750 GAKISSETLIEENTYLR 21.488 RIKEN cDNA 4933427L07 C47D12.2 *
Bm1_49765 GADGGTIPKRCELVKKK 21.607 chromosome 20 open reading
frame 43
C01A2.5 *
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are in excess of 60 potential substrates in this organism [55].
Similar genome sequence analysis has identified 62 putative
protein substrates for N-myristoylation in L. major [51,56] and
more than 40 substrates in P. falciparum [22]. Many of the
malaria targets have been validated experimentally in a recent
study [37].
In humans and other eukaryotes, including C. elegans,
approximately 0.5–0.8% of all proteins in the genome are
myristoylated [57]. The biological role of myristoylation in
nematodes is poorly understood and the effect of NMT inhibition
in these organisms is probably complex, likely involving the
functionality of many proteins that are essential for viability. This
is consistent with our genetic studies in C. elegans and the finding
that the majority of the predicted substrates in C. elegans display
multiple developmental defects and impaired survival in RNAi
screens. We predicted potential substrates in B. malayi encom-
passing a range of functions, including SRC-1 which encodes a
non-receptor tyrosine kinase involved in cell signaling pathways
specifying cell fate and division in C. elegans [58,59]. The majority
of the substrates are present in the proteome of one or more
developmental stages of B. malayi [60]. Collectively, these data
provide evidence for the importance of NMT activity in
nematodes and provide some insight into the many diverse
pathways that are likely dependent on myristoylated proteins. For
further development of NMT as a drug target it would be of great
interest to identify these proteins and evaluate the impact of
inhibition of NMT activity resulting from genetic or chemical
knockdown of the enzyme.
Myristoylation is an unexplored area for drug discovery in
nematodes. Our studies have shown for the first time that NMT is
a potential drug target in filarial parasites. The discovery of a
related family of lead molecules, originally identified as protozoan
NMT inhibitors, with activity against microfilariae and adult
worms is particularly exciting and highlights the potential value of
a repurposing approach to new drug discovery for filarial parasites.
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(NP_498326.1), S. cerevisiae (NP_013296.1), L. major
(AAG38102.1), Homo sapiens (AAH06376.1) and T. brucei
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